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Heart rate reductionHeart rates during ischaemia and reperfusion are possible determinants of reperfusion arrhythmias. We
used ivabradine, a selective If current inhibitor, to assess the effects of heart rate reduction (HRR) during
ischaemia–reperfusion on reperfusion ventricular arrhythmias and assessed potential anti-arrhythmic mecha-
nisms by optical mapping. Five groups of rat hearts were subjected to regional ischaemia by left anterior
descending artery occlusion for 8 min followed by 10 min of reperfusion: (1) Control n=10; (2) 1 μM of
ivabradine perfusion n=10; (3) 1 μM of ivabradine+5 Hz atrial pacing throughout ischaemia–reperfusion
n=5; (4) 1 μM of ivabradine+5 Hz pacing only at reperfusion; (5) 100 μM of ivabradine was used as a 1 ml
bolus upon reperfusion. For optical mapping, 10 hearts (ivabradine n=5; 5 Hz pacing n=5) were subjected
to global ischaemia whilst transmembrane voltage transients were recorded. Epicardial activation was mapped,
and the rate of development of ischaemia-induced electrophysiological changes was assessed. HRR observed
in the ivabradine group during both ischaemia (195±11 bpm vs. control 272±14 bpm, pb0.05) and at
reperfusion (168±13 bpm vs. 276±14 bpm, pb0.05) was associated with reduced reperfusion ventricular
ﬁbrillation (VF) incidence (20% vs. 90%, pb0.05). Pacing throughout ischaemia–reperfusion abolished the protec-
tive effects of ivabradine (100% VF), whereas pacing at reperfusion only partially attenuated this effect (40% VF).
Ivabradine, given as a bolus at reperfusion, did not signiﬁcantly affect VF incidence (80% VF). Optical mapping
experiments showed a delay to ischaemia-induced conduction slowing (time to 50% conduction slowing:
10.2±1.3 min vs. 5.1±0.7 min, pb0.05) and to loss of electrical excitability in ivabradine-perfused hearts
(27.7±4.3 min vs. 14.5±0.6 min, pb0.05). Ivabradine administered throughout ischaemia and reperfusion
reduced reperfusion VF incidence through HRR. Heart rate during ischaemia is a major determinant of reperfu-
sion arrhythmias. Heart rate at reperfusion alone was not a determinant of reperfusion VF, as neither a bolus of
ivabradine nor pacing immediately prior to reperfusion signiﬁcantly altered reperfusion VF incidence. This
anti-arrhythmic effect of heart rate reduction during ischaemia may reﬂect slower development of
ischaemia-induced electrophysiological changes.
© 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Ventricular arrhythmias, can occur within seconds of restoration
of blood ﬂow to previously ischaemic myocardium, as initially shown
by Tennant and Wiggers just under a century ago [1]. Reperfusion
after brief periods of ischaemia, lasting seconds to minutes, occurs in
the context of coronary artery vasospasm, or unstable angina, and is
associated with reperfusion ventricular arrhythmias [2]. Reperfusion
after longer periods of ischaemia lasting several hours occurs duringe for Translational and Exper-
mith Campus, Du Cane Road,
4 2075943015.
).
NC-ND license.percutaneous coronary intervention for patients with acute myocardial
infarction, which is also associated with reperfusion arrhythmias [3].
The arrhythmogenic mechanisms that underlie reperfusion ventricu-
lar tachycardia (VT) and ventricular ﬁbrillation (VF) are thought to relate
to the abrupt electrophysiological and biochemical changes brought
about by the restoration of blood ﬂow [4]. The reperfusion of ischaemic
myocardium triggers the rapid and heterogeneous restoration of action
potentials towards that of pre-ischaemic levels [5], and themarked spatial
heterogeneity in action potentials immediately after reperfusion can pre-
dispose to re-entry [6]. Reperfusion can also lead to intracellular calcium
overloading [7], which then increases the electrogenic forward mode
activity of the sarcolemmal sodium–calcium exchanger, and can cause
Phase 4 delayed after depolarisations and triggered action potentials.
It has been shown in experimental studies that heart rate
during acute ischaemia–reperfusion is an important determinant of
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rates predisposing to arrhythmias. These data suggest that a clinical
therapeutic strategy of heart rate reduction during ischaemia–reper-
fusion may reduce the incidence of reperfusion arrhythmias. Howev-
er, it remains unclear if the heart rate during ischaemia or during
reperfusion is more important in determining reperfusion arrhythmia
susceptibility, and conﬂicting experimental evidence exists in support
of either hypothesis [8,11].
Ivabradine (IVA) is a selective If current blocker with heart rate
lowering effects [12], clinically licensed for chronic stable angina and
chronic heart failure. Ivabradine treatment has also been shown to
reduce the incidence of cardiovascular death and hospital admissions
in a heart failure population in the SHIFT study [13], and it reduced
the number of coronary events in a subgroup of chronic stable angina
patients with heart rates of 70 beats per minute or greater in the
BEAUTIFUL study [14,15]. Based on preclinical data showing that re-
duced heart rates beneﬁcially impacted on reperfusion arrhythmia
risk [8–11], we hypothesised that ivabradine treatment may provide
anti-arrhythmic protection against reperfusion arrhythmias.
We assessed if heart rate loweringwith ivabradine can reduce the
incidence of reperfusion arrhythmias in an ex vivo rat model of acute
regional ischaemia–reperfusion.We also sought to clarify if the heart
rate during ischaemia or during reperfusion was more important
in determining reperfusion arrhythmia susceptibility, as this will
inﬂuence the timing of ivabradine administration in any potential
clinical therapeutic strategy. We performed studies using ivabradine
and atrial pacing in varying combinations to address these questions.
We then performed optical mapping of transmembrane voltage to
investigate the mechanism by which heart rate may inﬂuence reper-
fusion arrhythmogenesis.
2. Materials and methods
2.1. Ethical approval
This work was performed in accordance with standards set out in
the UK Animals (Scientiﬁc Procedures) Act 1986.
2.2. Acute ischaemia–reperfusion studies
Thirty-ﬁve adult male Sprague–Dawley rats (weight 250–300 g)
were sacriﬁced, and hearts were rapidly excised and retrogradely per-
fused via the aorta with modiﬁed Krebs–Henseleit solution (in mmol/
l: NaCl 118.5, CaCl2 1.85, KCl 4.5, glucose 11.1, NaHCO3 25, MgSO4 2.5,
NaH2PO4 1.4) gassed with 95% O2/5% CO2 at 37 °C±0.5 °C and
pH 7.35±0.05. Perfusion pressure through the aorta was constant
and maintained between 90 and 100 cm H2O. Unipolar electrograms
were recorded at a sampling frequency of 1 kHz using a silver electrode
placed at the left ventricular anterolateral wall and a reference
electrode attached to the aortic cannula. Electrodes were connected to
a Bioampliﬁer and a PowerLab data acquisition system (AD Instru-
ments, Sydney, Australia). During the stabilisation phase, a 6.0 Ethicon
prolene ligature (Johnson & Johnson Ethicon, Livingston, UK) was
placed around the left anterior descending (LAD) artery 1–2 mm distal
fromwhere it emerges beneath the left atrium, initially without tension
(Fig. 1A).
The hearts were stabilised for 15 min before being randomly allo-
cated to one of ﬁve treatment groups (Fig. 2D). Atrial pacing
and ivabradine (IVA) were used to control heart rates during the
experiments. Right atrial pacing was used and ventricular pacing
avoided as ventricular pacing per se has been shown to facilitate the
development of reperfusion arrhythmias [16]. An ivabradine con-
centration of 1 μMwas selected for the acute ischaemia–reperfusion
experiments based on concentration–response studies showing an
18±4% reduction in sinus heart rate with this concentration
(see Figs. 2A–C and Data supplement), a similar magnitude to theclinical heart rate reduction (HRR) reported in the SHIFT trial
(~16% HRR) [13]. Ivabradine was kindly provided by Servier Labora-
tories, France.
Group 1 — Control (n=10): Hearts were subjected to 8 min of
ischaemia followed by 10 min of reperfusion, without pacing or
ivabradine.
Group 2 — 1 μM of ivabradine (IVA, n=10): Hearts were per-
fused with 1 μM of ivabradine, starting 5 min before ischaemia
onset and then throughout the experiment. This group had
reduced heart rates at ischaemia onset, throughout the duration
of ischaemia and at reperfusion.
Group 3— Ivabradine bolus at reperfusion (n=5): Hearts were per-
fused with a 1 ml bolus of 100 μM of ivabradine 1 min prior to
reperfusion. This group had reduced heart rates at reperfusion only.
Group 4 — 1 μM of ivabradine+atrial pacing during ischaemia and
reperfusion (n=5): Hearts were perfused with 1 μM of ivabradine,
starting 5 min before ischaemia onset and throughout the experi-
ment, matching Group 2. In addition, hearts were paced from
the right atrium at 300 beats per minute (bpm) from the onset of
ischaemia until the end of the experiment.
Group 5 — 1 μM of ivabradine+atrial pacing across reperfusion
(n=5): Hearts were perfused with 1 μM of ivabradine, starting
5 min before ischaemia onset and throughout the experiment,
matching Groups 2 and 4, and were paced at 300 bpm starting
30 s before reperfusion and for a further minute after onset of
reperfusion.
To generate regional ischaemia, the prolene ligature placed earlier
around the LAD artery was tightened using a polythene occluder tube
placed over the suture, thereby occluding ﬂow through the artery
(Fig. 1A). Successful occlusion of the arterywas conﬁrmed by a reduction
in coronary ﬂow rate (CFR) of >30% as assessed by measuring the
coronary efﬂuent, in conjunction with an alteration in the axis and mor-
phology of the unipolar electrogram. Hearts were subjected to 8 min
of regional ischaemia, before the suture was released to restore ﬂow
across the LAD artery. We selected 8 min of ischaemia because the rela-
tionship between ischaemia duration and reperfusion VT/VF incidence is
“bell-shaped” [8], with our data showing that 8 min of ischaemia is on
the steep part of this bell-shaped relationship (see Data supplement).
Reperfusion was conﬁrmed by an increase in CFR towards that of
pre-ischaemic values. The reperfusion phase was continued for 10 min
with continuous electrogram monitoring for all 5 groups. The incidence
of ventricular arrhythmias during the ischaemia and reperfusion were
recorded. Ventricular arrhythmias were classiﬁed according to the
Lambeth Convention guidelines [17]. The primary endpoints were
reperfusion VT incidence and reperfusion VF incidence.
2.3. Optical mapping studies during global no-ﬂow ischaemia
In order to assess the effects of heart rate on the rate of development
of ischaemia-induced electrophysiological changes, optical mapping
experiments (Fig. 1B) were performed in a global no-ﬂow ischaemia
model. Ten hearts were perfused at ﬁxed coronary ﬂow rates
(15 ml/min) inside a perspex optical mapping chamber (Cairn Re-
search, Faversham, UK) (Fig. 1C). Following a 15-minute stabilisation
period, the hearts were stained with RH237, a potentiometric dye
(25 μl of 1 mg/ml RH237 in dimethyl sulfoxide; Invitrogen, UK),
and perfused with an excitation–contraction uncoupler, 10 μM of
blebbistatin (Sigma-Aldrich, UK), to eliminate motion artefact [18].
To record optical action potentials, the hearts were excited with
light-emitting diodes (excitationwavelength 530 nm), and the emitted
ﬂuorescent light was collected and split with a dichroic mirror at
630 nm. The shorter wavelength light portion was focused onto a
Fig. 1. Acute ischaemia–reperfusion and optical mapping experiments: (A) Regional ischaemia–reperfusion experiments. The left anterior descending (LAD) artery was temporarily
occluded to generate ischaemia and then released for reperfusion. (B) Experimental set-up for optical mapping experiments. (C) Heart in optical mapping chamber, with the optical
mapping ﬁeld shown on the anterior surface of the left ventricle. (D) Representative ventricular epicardial optical recordings of transmembrane voltage (Vm) during sinus rhythm
(SR), ventricular tachycardia (VT) and ventricular ﬁbrillation (VF).
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wavelength portion was passed through an emission ﬁlter (660 nm)
and detected using a Hamamatsu 256 (16×16) photo-diode array
detector (Cairn Research, Faversham, UK), at sampling rate of 1 kH
with a spatial resolution of 1 mm. Signals were recorded during pacing
from the left ventricular freewall (cycle length 200 ms, stimulus 1 mA).
The hearts were randomised to one of the following two groups,
chosen to produce two extremes of heart rates during global no-ﬂow
ischaemia:
Group 1 — Ivabradine (IVA): Hearts were perfused with 1 μM of
ivabradine, starting 5 min before the onset of global ischaemia, to
reduce heart rate during global ischaemia (n=5).
Group 2 — Pacing at 300 bpm: Hearts were paced at 300 beats per
minute (bpm) from the onset of ischaemia through to the end ofthe experiment, to increase heart rate during global ischaemia
(n=5).
The hearts were then subjected to global no-ﬂow ischaemia
and transmembrane voltage (Vm) transients were recorded every
30 s during ventricular pacing to study the changes induced by
ischaemia. The primary endpoint was the time to loss of electrical
excitability with ventricular pacing. The secondary endpoints were
the conduction velocity after 10 min of global ischaemia and time
to 50% reduction in CV.
2.4. Optical mapping data analysis
Optical mapping data were acquired using QRecord software and
analysed off-line using Optiq software (Cairn Research Ltd, Kent,
Fig. 2. Ivabradine reduced sinus heart rate, with reversal by atrial pacing: (A–C) Ivabradine concentration–response studies: (A) Sinus heart rate, (B) absolute heart rate reduction and
(C) percentage heart rate (HR) reduction with increasing concentrations of ivabradine (n=3). Ivabradine at a concentration of 1 μM reduced heart rate by 51±9 bpm (18±4%).
(D) Study protocol for acute ischaemia–reperfusion experiments showing the ﬁve groups used to assess the effects of heart rate during ischaemia and reperfusion on reperfusion
arrhythmia incidence. (E) Heart rate pre-ischaemia and during regional ischaemia were different for the ﬁve study groups. (F) Heart rate at onset of ischaemia. (G) Heart rate at
reperfusion. (H) Percentage coronary ﬂow reduction with regional ischaemia (*pb0.05, **pb0.01, ***pb0.001 vs. control).
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were derived, using MATLAB R2010a software (MathWorks, Massa-
chusetts, USA), using methods previously described [19].
2.5. Statistical analysis
Statistical analyses were performed using Prism 5.0 software
(GraphPad Software, California, USA). The logrank test was used to
compare freedom from reperfusion arrhythmias between groups.
Analysis of variance (ANOVA) tests were performed to compare
means between multiple groups and post-hoc Tukey's test was used
if ANOVA was signiﬁcant. Pearson's correlation was used to correlate
mean heart rates with reperfusion arrhythmia incidence. A p-value of
b0.05 was considered statistically signiﬁcant. All values shown are
mean±S.E.M., unless otherwise stated.
3. Results
3.1. Acute ischaemia–reperfusion studies
3.1.1. Ivabradine reduced sinus heart rate, with reversal by atrial pacing
Figs. 2E–G and Table 1 show the heart rates for these ﬁve study
groups. Group 1 was the control group, and had heart rate governed
by sinus rhythm. Group 2 was perfused with ivabradine and, com-
pared with control, had reduced heart rates at ischaemia onset
(pb0.05), during ischaemia (pb0.05) and at reperfusion (pb0.05).
Group 3 had boluses of ivabradine at reperfusion only, with signiﬁ-
cantly slower heart rates limited to the reperfusion phase compared
to the control (pb0.05). Group 4 had ivabradine perfusion with si-
multaneous atrial pacing throughout I–R, so compared with Group 2
(ivabradine only), had increased heart rates during ischaemia
(pb0.05) and at reperfusion (pb0.05). Group 5 had ivabradine perfu-
sion with pacing across reperfusion, and compared with Group 2, had
increased heart rates restricted to the reperfusion phase (pb0.05).
3.1.2. Ivabradine reduced reperfusion VT and VF via selective heart rate
reduction
These differences in heart rates during ischaemia and at reperfu-
sion resulted in varying incidences of reperfusion arrhythmias across
the groups, as shown in Fig. 3. The percentage reduction in coronary
ﬂow rate, which is a measure of the size of the ischaemic zone and
a potential confounding variable, was not different between groups
(Fig. 2H).
Ivabradine perfusion to lower heart rate throughout ischaemia
and reperfusion (Group 2) reduced reperfusion VF incidence to 20%
compared to 90% in control hearts (Group 1) (pb0.05), and reduced
reperfusion VT incidence from 90% to 40% (pb0.05) (Figs. 3A–D).
Fig. 3E shows an example of a control heart developing reperfusion
VT and VF several seconds after reperfusion, and an ivabradine-
treated heart with slower heart rate pre-reperfusion developing a
single ventricular premature beat without VT or VF following
reperfusion.
In order to investigate if the anti-arrhythmic effects of ivabradine
(Group 2) were due to its heart rate reduction effects or due to anoth-
er mechanism independent of heart rate, we compared the arrhyth-
mia incidence with that of Group 4, where atrial pacing wasTable 1
Differences in heart rates between the ﬁve study groups: Heart rate (HR) at ischaemia ons
(⁎pb0.05, ⁎⁎pb0.01, ⁎⁎⁎pb0.001 vs. Group 1 — Control; #pb0.05, ##pb0.01, ###pb0.001 vs
HR at ischaemia onset
Group 1 309±13
Group 2 240±13⁎⁎
Group 3 329±21##
Group 4 235±20⁎
Group 5 243±18delivered at 300 bpm in addition to ivabradine perfusion. In this
group, atrial pacing with concomitant ivabradine administration
abolished ivabradine's anti-arrhythmic effect (100% VT, 100% VF).
These data suggest that the anti-arrhythmic effects of ivabradine in
this context can be attributed solely to its heart rate lowering effect.
3.1.3. Heart rate during reperfusion was not a determinant of reperfusion
arrhythmia susceptibility
Having established that ivabradine protected against reperfusion
arrhythmias through heart rate reduction, we investigated if heart
rate during reperfusion was important in determining reperfusion ar-
rhythmia susceptibility using Groups 3 and 5. A bolus of ivabradine
just before reperfusion to lower heart rate at reperfusion (Group 3)
did not signiﬁcantly reduce reperfusion VF incidence compared to
controls (80% vs. 90%) (Figs. 3A–D). Similarly, ivabradine perfusion
plus atrial pacing at reperfusion only to increase heart rate at reperfu-
sion (Group 5) did not signiﬁcantly increase reperfusion VF incidence
compared to ivabradine alone (Group 2) (40% vs. 20%). The arrhyth-
mia incidence in these groups suggests that heart rate at reperfusion
was not the critical variable accounting for the anti-arrhythmic effect
of ivabradine, as either increasing or reducing the heart rate at reper-
fusion failed to signiﬁcantly alter reperfusion VT/VF incidence.
3.1.4. Mean heart rate during ischaemia is a determinant of reperfusion
arrhythmia susceptibility
We then investigated if the mean heart rate during ischaemia is
important in determining reperfusion arrhythmia susceptibility. We
plotted mean heart rates over the course of 8 min of regional ischae-
mia for the ﬁve groups against reperfusion VT and VF incidence and
found excellent linear correlations between mean heart rate during
ischaemia and the subsequent reperfusion arrhythmia incidence
for both VT and VF, as shown in Fig. 4 (reperfusion VT: Pearson's
r2=0.96, pb0.05; reperfusion VF: Pearson's r2=0.98, pb0.05),
suggesting that mean heart rate during ischaemia is an important
determinant of reperfusion arrhythmogenesis.
3.2. Heart rate reduction slowed the development of ischaemia-induced
electrophysiological changes
Optical mapping studies were then performed to assess possible
mechanisms by which a reduction in mean heart rate during ischae-
mia can protect against reperfusion arrhythmias.
The optical mapping study was designed to create two groups
with different heart rates during global ischaemia. Heart rate was re-
duced in the ivabradine group (223±12 bpm) compared to paced
hearts (300 bpm) at onset of ischaemia (pb0.05). Heart rate slowed
progressively in the ivabradine group after onset of global ischaemia,
until a cessation of spontaneous activity by 5 min of global ischaemia,
whilst heart rate was maintained at 300 bpm throughout ischaemia
in the paced group.
These global no-ﬂow ischaemia experiments showed that heart
rate was an important determinant of the rate of onset and develop-
ment of ischaemia-induced electrophysiological changes, as shown in
Fig. 5. Hearts in the ivabradine group, which had signiﬁcantly slower
heart rates, had delayed onset of loss of electrical excitability
compared to paced hearts (pb0.05; Fig. 5A). The development ofet, mean heart rate during ischaemia and heart rate at reperfusion for the ﬁve groups
. Group 2 — Ivabradine).
Mean HR during ischaemia HR at reperfusion
273±14 276±14
191±11⁎⁎⁎ 168±13⁎⁎⁎
261±20# 201±29⁎
300±0### 302±0###
213±20 301±0###
Fig. 3. Ivabradine reduced the incidence of reperfusion VT and VF via heart rate reduction:
(A to D) Freedom from reperfusion VT, reperfusion VT incidence, freedom from reperfusion
VF and reperfusionVF incidence for theﬁve groups: Ivabradine (Group 2) improved freedom
from reperfusion VT/VF and reduced reperfusion VT/VF incidence compared to control
(Group 1). Atrial pacing (Group 4) abolished ivabradine's protective effects. An ivabradine
bolus at reperfusion (Group 3) did not signiﬁcantly alter arrhythmia incidence compared to
control. Atrial pacing only at reperfusion in addition to IVA (Group 4) did not signiﬁcantly
alter arrhythmia incidence compared to IVA perfusion (Group 2) (*pb0.05, **pb0.01,
***pb0.001 vs. control) (Group 1: n=10, Group 2: n=10, Group 3: n=5, Group 4: n=5,
Group 5: n=5). (E) Top: Electrogram trace showing the development of VT andVF following
reperfusion in a control heart. Bottom: Epicardial electrogram trace from an ivabradine-
treated heart, showing slower heart rate before reperfusion, a single ventricular ectopic
following reperfusion, and the absence of reperfusion VT/VF.
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ivabradine group compared to the paced group. Following 10 min of
global ischaemia, there was less conduction slowing in ivabradine-
perfused hearts compared to paced hearts (pb0.05; Fig. 5B). The time
to a 50% reduction in conduction velocity was twice as long in the
ivabradine group compared to the paced group (pb0.05; Fig. 5C). The
slower development of conduction slowing in the ivabradine group
can be seen in the series of activation maps in Fig. 5D.
4. Discussion
In this study, our four main ﬁndings were: (1) ivabradine reduced
the incidence of reperfusion VT and VF following regional ischaemia,(2) ivabradine's anti-arrhythmic effects were due to its selective
heart rate lowering effects, (3) the mean heart rate during ischaemia
was an important determinant of reperfusion arrhythmia susceptibil-
ity, and (4) slower heart rates during ischaemia delayed the develop-
ment of ischaemia-induced electrophysiological changes.
4.1. Ivabradine reduced the incidence of reperfusion VT and VF
Our results showed that the administration of ivabradine signiﬁ-
cantly lowered the incidence of reperfusion VT and VF following
a period of regional ischaemia, with a 50% absolute reduction in VT
incidence and a 70% reduction in VF incidence. Our data support
existing studies in the literature showing that reduced heart
rates during acute ischaemia–reperfusion were associated with re-
ductions in reperfusion arrhythmias [8–11]. The results from our ex-
periments also ﬁt with recent studies suggesting that ivabradine
can protect against acute ischaemia-induced arrhythmias [20,21].
Vaillant et al. demonstrated that ivabradine reduced heart rate by
31% and increased VF thresholds by 2.9-fold in pigs subjected to
coronary artery occlusion [20]. The protective effect of HRR against
ischaemia-induced arrhythmias was also previously shown in stud-
ies using propranolol [22,23]. However the anti-arrhythmic effects
of propranolol are more complex than HRR alone, and include
reduced β1-Gs-cyclic adenosine monophosphate (cAMP)-mediated
cytosolic calcium and reactive oxygen species overload, and β2-Gi
stimulus trafﬁcking [24]. We have shown that, in addition to pro-
tecting against ischaemia-induced arrhythmia, ivabradine can also
reduce arrhythmias during the subsequent reperfusion phase.
Taken together, these results point towards a potential role for
ivabradine as an anti-arrhythmic agent in preventing arrhythmias
during the different phases of acute ischaemia–reperfusion.
4.2. The anti-arrhythmic effects of ivabradine were due to heart rate
reduction
In our studies, the anti-arrhythmic protection conferred by
ivabradine treatment was completely abolished when atrial pacing
was delivered to maintain heart rates similar to those in the control
group. This was similarly observed by Vaillant et al., where the pro-
tective effects of ivabradine against ischaemia-induced arrhythmias
were also mainly due to heart rate reduction [20]. In those experi-
ments, there was only a small increase in VF thresholds if pacing
was employed to maintain heart rate during acute ischaemia. How-
ever, Heusch et al. demonstrated that ivabradine's protection during
acute ischaemia–reperfusion can go beyond heart rate reduction
[25]. In a porcine model of ischaemia–reperfusion, they showed
that ivabradine can signiﬁcantly reduce infarct size, and that
although the beneﬁt of ivabradine on myocardial ﬂow and function
were eliminated by atrial pacing, part of the reduction in infarct
size by ivabradine was unaffected by atrial pacing. Our data would
suggest that although the reduction in infarct size by ivabradine
may be due to multiple mechanisms not restricted to its effects on
heart rate, its anti-arrhythmic effects are predominantly due to
heart rate reduction.
4.3. Mean heart rate during ischaemia is a determinant of reperfusion
arrhythmias
We showed that heart rate during ischaemia is more important in
determining reperfusion arrhythmias susceptibility compared with
heart rate at reperfusion. It was previously unclear if the heart rate
during ischaemia or at reperfusion was more important and experi-
mental studies had thus far produced conﬂicting results. Studies in
isolated rat hearts showed that atrial pacing during acute regional
ischaemia caused a rate-related increase in reperfusion arrhythmia
incidence, suggesting that heart rate during ischaemia was more
Fig. 4.Mean heart rate during ischaemia is the main determinant of reperfusion arrhythmias: (A) Reperfusion VT incidence and (B) reperfusion VF incidence plotted on the y-axes
against the mean heart rates during ischaemia (standard errors bars shown) for the 5 experimental groups on the x-axes. There were excellent correlations between reperfusion VT
and VF incidence with mean heart rate during ischaemia (Pearson's r2=0.96, p=0.003 and Pearson's r2=0.98, p=0.001 for reperfusion VT and VF respectively).
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and metoprolol can protect against reperfusion arrhythmias due to
its negative chronotropic effects during ischaemia [9,10]. On the con-
trary, Zuanetti et al. presented evidence suggesting that it may be the
heart rate at reperfusion that is more important in determining re-
perfusion arrhythmia susceptibility [11]. They showed that vagal
stimulation to reduce heart rate at reperfusion reduced reperfusion
VF, whilst concomitant pacing to maintain heart rate during vagal
stimulation signiﬁcantly attenuated the observed anti-arrhythmic
effect.
The discrepancies in these studies have been attributed to the dif-
ferences in species, duration of ischaemia and in the magnitude ofFig. 5. Ivabradine slowed the onset of acute ischaemia-induced electrophysiological change
compared to the paced group. (n=5 in each group, *pb0.05). (B) The degree of conduction s
was a delay in the time to a 50% reduction in conduction velocity in the ivabradine group. (D
slowing with global ischaemia. Conduction velocity slowing was faster in the paced group cheart rate reduction. Another possible reason is that the interventions
used to lower heart rate in these studies, β-adrenoreceptor blockers
and vagal stimulation, have multiple other effects in addition to
their negative chronotropic effects. Their broad actions make it
difﬁcult to discern if their anti-arrhythmic effects in these studies
were due to the lowering of heart rate or to another effect. Using
ivabradine, a selective heart rate lowering agent, we were able to
dissect out the relative importance of heart rates during ischaemia
and at reperfusion on reperfusion arrhythmia incidence, and we
demonstrated that heart rate during ischaemia was the important de-
terminant of reperfusion arrhythmias by showing an excellent corre-
lation between mean heart rate during ischaemia with reperfusions: (A) There was a delay in time to loss of electrical excitability in the ivabradine group
lowing was reduced in the ivabradine group after 10 min of global ischaemia. (C) There
) Isochronal activation maps during ventricular pacing showing progressive conduction
ompared to the ivabradine group (red is early activation, blue-violet is late activation).
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study by Heusch et al. [25], where they showed that ivabradine
administration just before reperfusion can still reduce infarct size.
This difference may be explained by the difference between the
mechanism of protecting against reperfusion arrhythmias and that
of reducing infarct size, and the timescale of both complications of
reperfusion. Arrhythmias usually occur within the ﬁrst few seconds
of reperfusion, whereas reperfusion-induced cardiomyocyte injury,
apoptosis and/or necrosis occur on a timescale of minutes to hours,
allowing time for ivabradine to exert a protective effect not possible
in the narrow time window of ventricular arrhythmia initiation. Our
ﬁndings highlight the importance of the timing of administration of
ivabradine if this therapeutic strategy is to be translated into clinical
practice.
4.4. Heart rate reduction during ischaemia delayed the onset of
ischaemia-induced electrophysiological changes
The concept that heart rate reduction is beneﬁcial during ischaemia
is often based on the hypothesis that lowering heart rate causes a reduc-
tion in myocardial energy consumption and can attenuate the severity
of ischaemia [8]. Ceconi et al. demonstrated that heart rate reduction
with ivabradine signiﬁcantly reduced cardiac energy consumption,
preserved redox potentials during ischaemia, and enhanced recovery
at reperfusion [26].
We performed optical mapping experiments to investigate the
potential mechanisms through which heart rate reduction during is-
chaemia with ivabradine protected against reperfusion arrhythmias.
Having established the anti-arrhythmic beneﬁts of HRR in amodel of re-
gional ischaemia, we wanted to investigate how HRR affected the myo-
cardial ischaemia-induced changes in general. A global ischaemiamodel
was selected because the uniform ischaemia throughout the heart in a
global ischaemia model facilitated the study of ischaemia-induced
electrophysiogical changes such as conduction slowing, although it
does not recapitulate the reperfusion–arrhythmias associated with re-
gional ischaemia–reperfusion.
Our opticalmapping experiments showed that increased heart rates
were associated with accelerated onset of ischaemia-induced changes,
including earlier loss of electrical excitability and greater degrees of
conduction slowing. These results provide a possible mechanism for
the observation that reduced heart rates during ischaemia were associ-
ated with reduced reperfusion arrhythmias. Acute ischaemia is known
to cause progressive electrophysiological changes, including a reduction
in action potential duration, a reduction in membrane excitability
and the slowing of conduction [27,28]. Slowing the development of
ischaemia-induced electrophysiological changes by lowering heart
rate with ivabradine would be expected to lead to smaller magnitudes
of changes in action potentials and conduction velocities with reperfu-
sion, which would be expected to be anti-arrhythmic [4]. Although
not directly studied in our optical mapping experiments, the delay
in ischaemia-induced changes may lead to delayed generation of
reactive-oxygen species and reduced calcium overload, which can
then reduce the likelihood of triggered arrhythmias. The delayed
generation of reactive oxygen species may also reduce the opening of
both the inner mitochondrial anion channel (IMAC) and the mitochon-
drial permeability transition pore (mPTP), both key players in reperfu-
sion injury [29,30], which may then produce an anti-arrhythmic effect.
4.5. Selective heart rate lowering with ivabradine as a therapeutic strat-
egy to reduce reperfusion arrhythmias
The concentration of ivabradine we chose in our experiments pro-
duced similar mean heart rate reductions at baseline to that observed
of clinical trials. Our ﬁndings suggest that ivabradine may be potentially
useful clinically to reduce the incidence of reperfusion arrhythmias fol-
lowing regional ischaemia–reperfusion.We also showed that the timingof ivabradine administration is critically important as it would be neces-
sary to administer the drug early enough during acute ischaemia to
lower the mean heart rate over the ischaemic period to have an impact
on reperfusion arrhythmia incidence. In the context of primary percuta-
neous coronary interventions (PCI) for myocardial infarction, a possible
scenario would be to administer ivabradine as a bolus in the ambulance
before arrival at the hospital to reduce heart rate before the primary PCI
procedure.
In cases of unstable angina, patients may be treated with ivabradine
upon admission to hospital to reduce heart rates in advance of potential
acute ischaemic episodes, whereas patients with arrhythmias due to
stable angina or coronary vasospasm may beneﬁt from long-term
ivabradine administration. Stable patients with coronary artery disease
on ivabradine may also beneﬁt from reduced arrhythmic risk during
acute episodes of ischaemia–reperfusion as a result of chronically re-
duced heart rates, though it has to be noted that no signiﬁcant reduc-
tions in sudden cardiac death (SCD) were reported in the BEAUTIFUL
and SHIFT trials [13–15]. This may be because these trials were under-
powered to detect differences in SCD rates, and also because SCD in
heart failure is due to multiple causes, not restricted to ischaemia–
reperfusion.
4.6. Study limitations
In our experiments, we selected the ischaemia duration of 8 min
prior to reperfusion for reasons described above. This duration is
brief compared to the durations of ischaemia seen in cases of
myocardial infarction before primary PCI, and it remains to be fully
determined if the strategy of heart rate reduction is anti-arrhythmic
in settings of longer ischaemia durations. Our ﬁndings may be more
directly applicable to unstable angina and intermittent stable angina
or coronary vasospasm, where the durations of ischaemia are brief.
Our opticalmapping studieswere performed in the global ischaemia–
reperfusion model, which therefore did not allow detailed evaluation
of themechanism(s) of reperfusion arrhythmias generated after regional
ischaemia–reperfusion.
4.7. Conclusions
We demonstrated that reducing heart rate during acute ischae-
mia reduced the incidence of reperfusion arrhythmias, and we
propose that the anti-arrhythmic effects of ivabradine may be medi-
ated in part by slowing the development of ischaemia-induced elec-
trophysiological changes. Ivabradine, which is licensed for chronic
stable angina and chronic heart failure, may be useful in the clinical
setting to prevent reperfusion arrhythmias if given early enough
during the course of acute ischaemia-infarction before primary PCI,
andmay also be protective against reperfusion arrhythmias in unsta-
ble angina and coronary vasospasm.
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